CD44 and neoplasm: Similarly, si-hVDAC1 treatment of A549-derived tumours greatly decreased the expression of ABCG2, SOX2, CD44, CD144, CD133, KLF4, Oct3/4, EPCAM and Nanog, also as evaluated by IHC, immunoblotting or q-RT-PCR (Figure 4E–H, Figure S1B).